Merck And J&J Settle Remicade Dispute By Redrawing The Map
This article was originally published in The Pink Sheet Daily
Executive Summary
Rather than let an arbitration panel decide the fate of two anti-TNF drugs, Merck surrenders many territories but holds onto Europe.
You may also be interested in...
FDA Approves Simponi For Ulcerative Colitis
J&J received approval to market a second TNF inhibitor to treat the bowel disorder. The authorization comes as Simponi’s increasing sales point toward blockbuster status.
J&J Says Penalties In Arkansas Risperdal Case ‘Excessive,’ Seeks New Trial
Argues that Arkansas Medicaid spent less than $10 million on Risperdal, but the fine imposed by a state judge for deceptive marketing practices would exceed $1.2 billion.
FDA Warns Again Of Rare Cancer Associated With TNF Blockers
FDA is asking for an additional round of label changes for the tumor necrosis factor inhibitor class, as a consequence of mounting evidence of cases of a rare and usually fatal type of lymphoma in patients taking the drugs.